Issue: July 2017
May 19, 2017
2 min read
Save

Top 10 IBD Research Shared at DDW

Issue: July 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Created during Digestive Disease Week 2010, World IBD Day is coordinated by the European Federation of Crohn’s and Ulcerative Colitis Associations and led by patient organizations spanning 38 countries and four continents, with the goal of raising awareness and improving the lives of people living with inflammatory bowel disease.

To contribute to this effort, the editors of Healio Gastroenterology have compiled a roundup of new research in IBD recently presented at this year’s DDW meeting in Chicago.

Crohn’s patients treated with anti-TNFs have lower risk for death than those treated with corticosteroids

Patients with Crohn’s disease who were treated with anti-TNF agents showed significantly lower risks for death, cardiovascular events and hip fracture compared with patients treated with long-term corticosteroids. Read more

JAK1 inhibitor shows promise in refractory Crohn’s

Upadacitinib effectively induced remission on various levels in patients with Crohn’s disease who almost all previously failed anti-tumor necrosis factor medications in a randomized controlled trial. Read more

IL-23 inhibitor maintains response, remission in Crohn’s disease

Risankizumab was well tolerated and effective for maintaining clinical and endoscopic remission and response in patients with moderate-to-severe Crohn’s disease, according to the results of a phase 2 open-label randomized controlled trial. Read more

VIDEO: Top take-aways in IBD therapies presented at DDW

William J. Sandborn, MD, professor of medicine, chief of the division of gastroenterology and director of the University of California San Diego Inflammatory Bowel Disease Center, recaps the most significant advances in therapies for inflammatory bowel disease presented at the meeting. Watch now

Vitamin D status does not impact CD, UC

Researchers observed no association between vitamin D status and the development of Crohn’s disease or ulcerative colitis, suggesting that vitamin D deficiency does not significantly affect the etiology of inflammatory bowel disease. Read more

Family history of IBD linked to younger diagnosis, complications

Researchers associated close-relative family history of Crohn’s disease with earlier diagnosis of Crohn’s disease in patients and increased risk of related complications while, overall, family history of inflammatory bowel disease predicted a younger age of diagnosis. Read more

Model predicts 80% of patients with Crohn’s at risk for complications

The PROSPECT model predicted more than 80% of patients with Crohn’s disease have a moderate to high risk of developing related complications within 3 years of analysis. Read more

VIDEO: Simplified text message-based telemedicine system improves adherence in IBD patients

Raymond Cross, MD, associate professor of medicine in the department of gastroenterology and hepatology, and director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine, discusses his research on the efficacy of a text message-based telemedicine system for IBD patients. Watch now

Capsule endoscopy bests MRE in detecting proximal small bowel Crohn’s

While capsule endoscopy, magnetic resonance enterography and small bowel intestinal contrast ultrasound resulted in comparable diagnostic yield for detection of small bowel Crohn’s disease, capsule endoscopy was superior to MRE for detecting proximal disease. Read more

Multiple HBV vaccines superior for seroconversion failure in patients with IBD

Patients with inflammatory bowel disease who failed seroconversion following initial hepatitis B vaccine were more likely to achieve higher titer levels after three vaccine doses compared with those who received only one or two dose. Read more